The Cancer Center is divided into eleven specialized cancer centers. In order to take account of the further development of oncology, these are supplemented by two networks of excellence that serve as cross-sectional services. By establishing these two networks of excellence, our Cancer Center has entered a new era of oncology to ensure that our patients receive individual, interdisciplinary care based on the latest findings.
The networks interact closely with the individual specialized cancer centers and develop guidelines for diagnostics, therapy and side effects management. They serve as coordination centers for clinical and translational research projects and both have established their own cancer boards.
The Immunotherapy Board meets once a month. Here, immunotherapy patients are discussed individually by the participating specialists from different disciplines, and therapies are determined. In doing so, great care is taken to control or avoid the side effects of the therapy. In addition, new immune strategies should be intelligently combined with existing therapeutic approaches in order to achieve maximum effect.
The continuous updates of shared knowledge and clinical expertise benefit patients, while the therapeutic strategies are constantly updated in line with the international standards. We also aim to participate in innovative studies in close cooperation with the referring doctors in the region.
Prof. Jörg Halter
Dr. Kathleen Jahn
Kaderärztin, ärztliche Leitung interventionelle Pneumologie
Prof. Dr. Gabriela Kuster Pfister
Dr. Lara Valeska Maul-Duwendag
Prof. Jan Hendrik Niess
Leitender Arzt Gastroenterologie/Hepatologie
Since September 2015, the Molecular Tumor Board is the first of its kind in Switzerland to be held every two weeks. Therapy decisions are made here based on the genomic sequencing of tumors. The sequencing data is interpreted by the molecular pathologists, biologists and medical geneticists in order to make therapeutic decisions together with the medical oncologists and hematologists.
The well-established Tumor Board discusses patient findings from a variety of disciplines. For example, benign rheumatology diseases are also discussed in order to take advantage of the Board’s interdisciplinary nature.
Associate Prof. Dr. med. Dr. phil. Sacha Rothschild
Thursday: 2:30 p.m.–4:30 p.m.
University Hospital Basel
Tel. +41 61 265 50 74/59
PD Dr. Benjamin Kasenda